---
schema_version: "secwatch.filing_event.v1"
accession: "0002007919-26-000030"
form_type: "8-K"
ticker: "INBX"
cik: "0002007919"
company_name: "Inhibrx Biosciences, Inc."
filed_at: "2026-06-03T20:02:12+00:00"
generated_at: "2026-06-03T20:04:29.687519+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.05
calibrated_materiality_score: 0.05
confidence: "high"
source: SEC EDGAR
---

# Inhibrx shareholders elect Forsyth and Manhard as directors, ratify BDO USA

## Summary
- Quorum of 11,541,232 shares (79% of outstanding) present at June 3, 2026 annual meeting.
- Douglas G. Forsyth elected Class II director with 7,608,469 votes for, 1,463,474 withheld.
- Kimberly Manhard elected Class II director with 9,035,097 votes for, 36,846 withheld.
- Ratification of BDO USA as auditor passed: 11,510,478 for, 30,347 against, 407 abstained.

## SEC filing metadata
- accession: 0002007919-26-000030
- form_type: 8-K
- ticker: INBX
- cik: 0002007919
- company_name: Inhibrx Biosciences, Inc.
- filed_at: 2026-06-03T20:02:12+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.05
- calibrated_materiality_score: 0.05
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000030/0002007919-26-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000030/inhibrx-20260603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002007919-26-000030
- JSON: https://secwatch.observer/filing/0002007919-26-000030.json
- Plain text: https://secwatch.observer/filing/0002007919-26-000030.txt

## Key facts
- Shareholder Votes
  Inhibrx Biosciences, Inc. shareholders approved Election of the following nominees as Class II directors of the Company at the 2026-06-03 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: Proposal 1 Election of the following nominees as Class II directors of the Company, nominated by the Company’s Board of Directors (the “Board of Directors”), each to serve until the 2029 Annual Meeting of Stockholders and until their respective successor is duly elected and qualified, or until their respective earlier death, resignation, or removal. Votes For Votes Withheld Broker Non-Votes Douglas G. Forsyth 7,608,469 1,463,474 2,469,289 Kimberly Manhard 9,035,097 36,846 2,469,289
  evidence_url: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000030/0002007919-26-000030-index.htm
- Shareholder Votes
  Inhibrx Biosciences, Inc. shareholders approved Ratification of the appointment by the Audit Committee of the Board of Directors of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-03 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: Proposal 2 Ratification of the appointment by the Audit Committee of the Board of Directors of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes For Votes Against Votes Abstained 11,510,478 30,347 407
  evidence_url: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000030/0002007919-26-000030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.